We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Systems for Determination of RNA Quality Compared by UK Standards Institute

By LabMedica International staff writers
Posted on 25 May 2010
A recent paper compared two methodologies for determining the quality of RNA before its use in microarray analytical systems. More...


The use of microarray technology has revolutionized the fields of molecular biology and genetics. However, concerns have been raised over the numerous potential sources of variation that can affect assay consistency and data quality. Previous studies have highlighted RNA integrity as one source that has a major effect on microarray data quality.

To date methods for determining RNA integrity have been extremely labor intensive and time consuming. Lately, an automated system, the Agilent Technologies (Santa Clara, CA, USA) 2100 Bioanalyzer, which utilizes a microfluidic-based platform has become available. An even more recent innovation is the Lab 901(Edinburgh, United Kingdom) ScreenTape R6K electrophoresis system. This system employs precast, multilane gels and microfluidics that enable semiautomated operation with simplified sample handling and reduced assay times.

The April 1, 2010, online edition of the journal BMC Research Notes contained a paper comparing the Agilent and Lab901 systems. Investigators at GLC Limited (London, United Kingdom), the United Kingdom's designated National Measurement Institute for chemical and biochemical analysis, analyzed a panel of intentionally degraded RNA samples on the two systems. They reported that results were similar and that the RIN values obtained with the Bioanalyzer were comparable to the SDV units generated by the Lab901 system.

The authors of the study concluded that, "The ScreenTape platform is comparable to the Bioanalyzer platform in terms of reproducibility and discrimination between different levels of RNA degradation. The robust nature of the SDV metric qualifies it as an alternative metric for RNA sample quality control, and a useful predictor of downstream microarray performance.”

Related Links:
Agilent Technologies
Lab 901
GLC Limited



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Turbidimetric Control
D-Dimer Turbidimetric Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.